RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
Items 601–700 of 764
Genetic studies yield clues to the pathogenesis of Langerhans cell histiocytosis
Zhang, L., & Moss, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.00568-2016 · Cited by 1
Jeong, J., Seo, K., & Kim, E. (2018) · BMC Cancer · doi:10.1186/s12885-018-4972-7 · Cited by 1
Mohamed, S. K., Karthikeyan, S., Ahsin, A., Omran, O. A., Mague, J. T., Al‐Salahi, R. A., & Bakri, Y. E. (2024) · ChemistrySelect · doi:10.1002/slct.202305179 · Cited by 1
Improved production of class I phosphatidylinositol 4,5-bisphosphate 3-kinase
Messing, S. A. J., Widmeyer, S. R. T., Denson, J.-P., Mehalko, J. L., Wall, V. E., Drew, M. R., Snead, K., Hong, M., Grose, C., Esposito, D., et al. (2024) · Protein Expression and Purification · doi:10.1016/j.pep.2024.106582 · Cited by 2
Costa, A. N., & Breccia, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.007 · Cited by 1
Costa, A. N., & Breccia, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.015 · Cited by 1
RetractedRosell, A., Krygowska, A. A., Pérez, M. A., Cuesta, C., Voisin, M.-B., de Paz, J., Sanz-Fraile, H., Rajeeve, V., Carreras‐González, A., Berral-González, A., et al. (2024) · eLife · doi:10.7554/elife.94590.4 · Cited by 6
Self-citationEndometrial Cancer Genetic Classification and Its Clinical Application
Ceppi, L., Dizon, D. S., & Birrer, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-64513-1_3 · Cited by 1
Interaction with the environment: Skin
Albini, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811659-3.00002-5 · Cited by 1
Specific Functions of ERK/MAPK Signaling in Brain Development and Neurocognition
Holter, M. C. (2019) · Cited by 1
Лактионов, К. К., Kazakov, A. M., Саранцева, К. А., Scherbo, D. S., & Koval, A. P. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2022-21-1-115-121 · Cited by 1
“) и контрольных точек клеточного цикла (механизмы апоптоза, ареста клеточного цикла) [8].”
Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma
Xie, H., Xing, C., Wei, B., Xu, X., Wu, L., Wu, J., Chen, L., Cao, G., Chen, H., Meng, X., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3643-4 · Cited by 1
Jefferies, M. T. (2017) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 1
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells
Barron, C. C. (2012) · Brock University Digital Repository (Brock University) · Cited by 1
Sudhan, D. R., Zotano, Á. G., Won, H. H., Ericsson, P. I. G., Servetto, A., Lee, K., Formisano, L., Guo, Y. P., Liu, Q., Kinch, L. N., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3362256 · Cited by 1
Maadi, H. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-74bb-e058 · Cited by 1
Rosell, A., Krygowska, A. A., Pérez, M. A., Cuesta, C., Voisin, M.-B., de Paz, J., Sanz-Fraile, H., Rajeeve, V., Carreras‐González, A., Berral-González, A., et al. (2024) · eLife · doi:10.7554/elife.94590 · Cited by 1
“PI3Ks are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits that can be categorized into three classes based on their structures and substrate specificities ( Castellano and Downward, 2011 ; Kok et al., 2009 ).”
Self-citationRosell, A., Krygowska, A. A., Pérez, M. A., Cuesta, C., Voisin, M.-B., de Paz, J., Sanz-Fraile, H., Rajeeve, V., Berral-González, A., Carreras‐González, A., et al. (2025) · eLife · doi:10.7554/elife.94590.3 · Cited by 1
Self-citationPhosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibitionPreprint
Ge, X., Singh, J., Li, W., Bishop, C. S., Ruiz, C. F., Bhattacharyya, M., Liu, Y., & Muzumdar, M. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.20.660715 · Cited by 1
Effects of modified bioactive pectins on colon cancer cells in vitro
Maxwell, E. G. (2014) · UEA Digital Repository (University of East Anglia) · Cited by 1
Hedberg, M. L. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Cox, A. D., & DeCristo, M. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.022
Translational control : mTOR signalling and the use of next-generation sequencing methods
Jackson, T. J. (2013) · Nottingham ePrints (University of Nottingham) · Cited by 1
The influence of methyl donor status on cervical cancer cell behaviour in vitro
Poomipark, N. (2013) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Regulation des Wachstums von BT474 humanen Mammakarzinomzellen durch Morphin
Weingaertner, I. R. (2013) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.15394
Augmentation of Ras-induced cell transformation : a new role for miR-200a in malignancy.
Becker, L. (2014) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/92
“Ras activity results in the activation of a wide array of downstream signaling pathways; however, the three main effectors that are activated by Ras are Raf, PI3K, and RalGEF [29].”
BackgroundInfluentialNeurofibromin and IL-4 as Regulators of T Cell Development, Function, and Homeostasis
Oliver, J. A. (2012) · Deep Blue (University of Michigan)
Genetic and Clinical Investigation of Noonan Spectrum Disorders
Ekvall, S. (2012) · DiVA (Digitala Vetenskapliga Arkivet)
Huang, S. (2013) · Digital Commons-TMC (Texas Medical Center)
Determinants of cell cycle progression in human mammary epithelial MCF12 cells
Ouertani, A. (2012) · UCL Discovery (University College London)
DIRECT EFFECTS OF METFORMIN ON PI3K AND RAS SIGNALING IN ENDOMETRIAL CANCER
Iglesias, & David, A. (2012)
Moore, J. (2015) · Brock University Digital Repository (Brock University)
Rad, E. (2015) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 1
Efeito dual de FGF2 e PMA em células HEK 293 transformadas por H-rasV12
da Silva, J. G. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2014.tde-20012015-085930
Jones, M. L. (2015) · Human Biology
Regulation of the retinoblastoma tumor suppressor by the novel Ras effector NORE1A.
Barnoud, T. (2015) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2320
“Apart from the above-mentioned Ras effectors, an increasing number of molecules that specifically interact with Ras have been described (108).”
BackgroundInfluentialThe Ras effector NORE1A forms a tumor suppressor complex with BRCA1.
Nelson, N. C. (2015) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2336
Rosim, M. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2016.tde-28042016-110618
Molecular Origin of Childhood Acute Lymphoblastic Leukemia
Waanders, E., Jongmans, M. C. J., & Mullighan, C. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-05798-9_7
Phosphatidylinositol 3-Kinase (PI3K) as a therapeutic target in NSCLC
Stamatkin, C. W. (2014) · UKnowledge (University of Kentucky)
The myeloma bone marrow environment and survival signaling
Khwaja, A., Quinn, J., & Yong, K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511862465.006
Use of genetically engineered mouse models in preclinical drug development
Creedon, H. (2015) · ERA
Salter, S. (2016) · Digital Repository Service (Northeastern University) · doi:10.17760/d20213052
Autophagy in siRNA-mediated PRKAR1A knockdown canine osteosarcoma cells
Wong, J. K. (2016) · The Atrium (University of Guelph)
Examination of the relevance of PI3K and PTEN pathway in Ustilago maydis.
Dalton, N. (2016) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2566
Jiwani, S. S. (2012) · STARS (University of Central Florida)
Anti-Cryptococcal Signaling in NK Cells
Xiang, R. F. (2017) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/24934
Molecular targets and targeted therapy
Dong, P. (2014) · doi:10.2217/fmeb2013.13.31
Ruicci, K. M. (2016) · University of Western Ontario Medical Journal · doi:10.5206/uwomj.v85i1.4203
Rodrigues, F. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2018.tde-26112018-080111 · Cited by 1
Castro, M. A. (2019) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/72425
Role of RAS signaling in Hedgehog-associated embryonal rhabdomyosarcoma
Bauer, J. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7239
Borges, C. R. P. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-17102018-154442
RAS Internal Tandem Duplication Disrupts GAP-binding to Activate Oncogenic SignalingPreprint
Nelson, A., Turbyville, T. J., Dharmaiah, S., Rigby, M., Yang, R., Columbus, J., Stephens, R. M., Sciacca, D., Onsongo, G., Sarver, A. E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/737098
“Recombinant RAS ITD binds to RAF1 but not to NF1 (neurofibromin 1) GAP To examine the effect of the ITD in RAS on its interaction with GAP and its effector proteins, we purified the recombinant GTPase domain (1-169) of KRAS with and without the ITD and carried out binding studies using isothermal titration calorimetry…”
BackgroundMethodMiranda, V. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2019.tde-01082019-085027
Understanding Behavior of Biological Network via Invariant Computation
Bashirov, R., & Ngandjoug, G. R. Y. (2019) · Advances in intelligent systems and computing · doi:10.1007/978-3-030-35249-3_50
Canonical Wnt Mechanisms in Neural Crest Induction
Perfetto, M. (2019) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7393
Untersuchung spezifischer Inhibitoren der PI3K-Signalkaskade zur Therapie des Lymphangioms
Blesinger, H. L. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8046
Alomran, S. S., Khattak, M. N. K., Khan, A. A., Abdallah, S. H., Fayyad, A. M., & Bajou, K. (2020) · Pakistan Journal of Zoology · doi:10.17582/journal.pjz/20191127131153
“However, this pathway is not directly targeted by miR-22-3p but it is cross linked with the PI3-K pathway (Castellano and Downward, 2011; Aksamitiene et al., 2012).”
BackgroundFGF8-mediated signaling regulates tooth developmental pace during odontogenesisPreprint
Lin, C., Ruan, N., Li, L., Chen, Y., Hu, X., Chen, Y., Hu, X., & Zhang, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.16.299388
INSULIN RESISTANCE RELATED SIGNALING PATHWAYS IN THE LIVER
Wang, Y. (2020)
Metabolic effects of oncogenic K-Ras in cancer cells
Bergner, R. (2018) · doi:10.25560/82596
Chandrashekhar, M. (2018) · TSpace (University of Toronto) · Cited by 2
Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancerPreprint
Diehl, J. N., Klomp, J. E., Snare, K. R., Blake, D. R., Hibshman, P. S., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.27.441678
“The second best characterized KRAS effector are phosphoinositide 3-kinases (PI3K) (13).”
BackgroundInfluentialDong, R. (2020) · KU ScholarWorks (The University of Kansas)
Woo, R. H. (2021) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/152423
Ercan‐Sencicek, A. G., Chennappan, S., Aromalaran, K., & Kontaridis, M. I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85765-9.00007-2
Role of HRas and NRas in murine lung development and neonatal survival
Fuentes‐Mateos, R. (2021) · Gredos (University of Salamanca) · doi:10.14201/gredos.148393
The role of histone 2B monoubiquitination (H2Bub1) in HER2-driven mammary carcinoma
Prokakis, E. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8486 · Cited by 1
O’Bryan, J. P. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733983450.793559493
Receptors | Platelet-Derived Growth Factor Receptor Family
Kovalenko, M. V., Kazlauskas, A., & Kitainda, V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00147-x
Tervonen, T. A., Pant, S. M., Belitškin, D., Englund, J. I., Närhi, K. M., Haglund, C. H., Kovanen, P. E., Verschuren, E. W., & Klefström, J. T. (2023) · doi:10.1158/0008-5472.c.6513103.v1
Data from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Askan, G., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2023) · doi:10.1158/0008-5472.c.6513651.v1
Holt, J. R., Walter, V., Yin, X., Marron, D., Wilkerson, M. D., Choi, H. Y., Zhao, X., Jo, H., Hayes, D. N., & Ko, Y. H. (2023) · doi:10.1158/1078-0432.c.6530319
Holt, J. R., Walter, V., Yin, X., Marron, D., Wilkerson, M. D., Choi, H. Y., Zhao, X., Jo, H., Hayes, D. N., & Ko, Y. H. (2023) · doi:10.1158/1078-0432.c.6530319.v1
Castellano, E., Rosell, A., Krygowska, A. A., Pérez, M. A., Voisin, M.-B., de Paz, J., Rajeeve, V., Berral-González, A., Cuesta, C., Swinyard, O., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3191814/v1
Self-citationIn the Pipeline: Emerging Therapy for MDS and MDS/MPN
Gill, H., Lee, E., & Mo, P. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_35
Revisiting RAS - Another Tough Nut That's Being Cracked by Cancer ResearchPreprint
Ghosh, S., Dey, A., Bhuniya, T., Paul, A., Hazra, S., Mondal, D. D., & Mahajan, A. A. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4600678
Genetic Testing in Endometrial Cancer
Singh, V., Sharma, A., & Rajender, S. (2023) · Springer eBooks · doi:10.1007/978-981-99-7028-5_16
Rosell, A., Krygowska, A. A., Pérez, M. A., Voisin, M.-B., de Paz, J., Sanz-Fraile, H., Rajeeve, V., Berral-González, A., Cuesta, C., Swinyard, O., et al. (2024) · eLife · doi:10.7554/elife.94590.1
Self-citationGoedert, L. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2019.tde-28062024-150024 · Cited by 1
Castellano, E., Rosell, A., Krygowska, A. A., Pérez, M. A., Voisin, M.-B., de Paz, J., Sanz-Fraile, H., Rajeeve, V., Berral-González, A., Cuesta, C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3191814/v3
Self-citationMediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Healy, F. M., Turner, A. L., Marensi, V., & MacEwan, D. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1441938 · Cited by 1
Treatments that Target Cell Communication
Vickers, E. (2024) · Wiley eBooks · doi:10.1002/9781119834090.ch3
Rosell, A., Krygowska, A. A., Pérez, M. A., Cuesta, C., Voisin, M.-B., de Paz, J., Sanz-Fraile, H., Rajeeve, V., Berral-González, A., Carreras‐González, A., et al. (2024) · eLife · doi:10.7554/elife.94590.2
Self-citationA comparative study of the PRF mediated cellular reaction of tumour cells
Parkhoo, K. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.87557
Activation of Serine/Threonine Protein Kinases and Phosphatases by Lymphocyte Antigen Receptors
Morel, P. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00091-0
RAS Family Interactions: The SHOC2-MRAS-PP1 Complex in Noonan Syndrome
del Río, I. B., & Rodriguez‐Viciana, P. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_21
Zou, Y., Han, D., Zhou, Y., Zhang, K., Gai, C., Zhang, P., Chai, X., Zhuo, X., Zhao, Q., & Zhu, L. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5082681
Thyroid C-Cell Biology and Oncogenic Transformation
Bagheri‐Yarmand, R., Grubbs, E. G., & Hofmann, M.-C. C. (2025) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-031-80396-3_3 · Cited by 1
Wang, R., Zhang, Y., Li, H., Liu, N., Liu, N., Li, S., Ren, B., Ye, F., 祭美菊, Hou, P., et al. (2026) · iScience · doi:10.21203/rs.3.rs-6629474/v1
Exploring MAPK and mTOR Pathways in Feline Thyroid Tumors
Monteiro, A., Gaspar, T. B., Borges, I., Canberk, Ş., Pinto, M., Pires, I. C. R., Soares, P., & Tavares, C. (2025) · Veterinary Sciences · doi:10.3390/vetsci12070617
Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer
Nath, S., Claridge, S. E., Granados, G. L., Assaad, M. A., Park, E. Y. H., Cavallo, J., Nuwere, U., Ackon, M. E., Boni, L. D., Baker, S. J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102218 · Cited by 1
The lnc-FANCI-2 intrinsically restricts RAS signaling in HPV16-infected cervical cancerPreprint
Liu, H., Yu, L., Majerčiak, V., Meyer, T., Yi, M., Johnson, P. F., Cam, M., Lowy, D. R., & Zheng, Z. (2025) · eLife · doi:10.7554/elife.102681.2
Miyan, J., Kumar, N., Moinuddin, Malik, S. A., Akif, U. M., Hameed, R., Riyazuddin, M., Dubey, P., Lal, J., Kumar, A., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03516-8 · Cited by 1
VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationPreprint
Hwang, S., Bae, M., Kim, J., Hyun, S. Y., Kim, K., Choe, J. H., Kim, M. J., Park, J. W., Jeong, S., Choi, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676456
Mao, Y.-Q., Liu, S., Qin, Z., Zhang, W., Jia, L., & Peng, X. (2025) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.70079 · Cited by 1
PI3K/PKB signaling network as a host target to enhance bacterial ingestion and clearance
Kim, L. W., Castillo, V., & Barbieri, A. (2025) · Biologia Futura · doi:10.1007/s42977-025-00298-8
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.